NOTICES

Week of July 13, 2015

- Registration Open for Mobile and Personal Technologies in Precision Medicine Workshop of the Precision Medicine Initiative Working Group of the Advisory Committee to the NIH Director, July 27-28, 2015 (NOT-OD-15-115) National Institutes of Health
- Notice of Corrections PAR-14-228 "NIH Science Education Partnership Award (SEPA) (R25)" (NOT-OD-15-116) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
- Notice About Updates to iEdison Regarding Reporting Requirements and Compliance Messages (NOT-OD-15-119) National Institutes of Health
- Request for Information (RFI): Input on NIAID Data Sharing Repository, Immunology Database and Analysis Portal (ImmPort), and Services (NOT-AI-15-045) National Institute of Allergy and Infectious Diseases
- Notice of Change in Application Review Cycle Frequency for the Superfund Hazardous Substance Basic Research and Training Program (P42) (NOT-ES-15-018) National Institute of Environmental Health Sciences
- Notice of Addition of High Throughput Screening to the Scope of PAR-15-070 "IGNITE: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)" (NOT-NS-15-031) National Institute of Neurological Disorders and Stroke
- NIA Announces Interest in Utilizing the CTSA Network - Trial Innovation Centers (TICs) to Study Alzheimers Disease and Other Aging-related Dementias (NOT-TR-15-016) National Center for Advancing Translational Sciences
- Notice: Standardized Test Scores Are No Longer Required in Biosketches for Individual Fellowship Applications (F30 and F31) (NOT-OD-15-120) National Institutes of Health
- Extramural Loan Repayment Program for Clinical Researchers (LRP-CR) (NOT-OD-15-121) National Institutes of Health
- Extramural Loan Repayment Program for Pediatric Research (LRP-PR) (NOT-OD-15-122) National Institutes of Health
- Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR) (NOT-OD-15-123) National Institutes of Health
- Extramural Clinical Research Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (LRP-IDB) (NOT-OD-15-125) National Institutes of Health
- NCCIH Policy on Support of Clinical Trials in NIH Pathway to Independence Award (K99/R00) (NOT-AT-15-007) National Center for Complementary and Integrative Health
- Notice of Change to Funding Opportunity Description in PAR-15-075 "Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)" (NOT-CA-15-022) National Cancer Institute
- Notice of NICHD's Participation in PA-15-010 "Spatial Uncertainty: Data, Modeling, and Communication (R01)" (NOT-HD-15-021) Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of Intent to Publish Funding Opportunity Announcements (FOAs) to Disseminate and Implement Patient-Centered Outcomes Research Findings through Clinical Decision Support (U18 and R18) (NOT-HS-15-010) Agency for Healthcare Research and Quality
- Notice of Correction to Award Information for RFA-MD-15-013 "NIMHD Transdisciplinary Collaborative Centers for Health Disparities Research Focused on Precision Medicine (U54)"
(NOT-MD-15-015)
National Institute on Minority Health and Health Disparities

- Notice of Intent to Publish a Funding Opportunity Announcement for the Exploratory Multi-site Palliative Care Research in Diverse Populations Utilizing the Palliative Care Research Cooperative (PCRC) Group (R21)

(NOT-NR-15-003)
National Institute of Nursing Research

- Clarifications and Updates for PAR-14-275 "State Occupational Health and Safety Surveillance Program (U60)"

(NOT-OH-15-007)
National Institute for Occupational Safety and Health

- Grant Regulation and Peer Review Contact Updates for PAR-14-227 "Workers’ Compensation Surveillance (U60)"

(NOT-OH-15-008)
National Institute for Occupational Safety and Health

- Notice of Updates for PAR-12-200 "NIOSH Small Research Grant Program (R03)" regarding Extension of the Expiration Date, and Change of Peer Review Contact

(NOT-OH-15-009)
National Institute for Occupational Safety and Health

- Notice of Updates for PAR-12-252 "NIOSH Exploratory/Developmental Research Grant Program (R21)" regarding: Extension of the Expiration Date, and Change of Peer Review Contact

(NOT-OH-15-010)
National Institute for Occupational Safety and Health

PROGRAM ANNOUNCEMENTS

- **TITLE:** Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02)
  (PAR-15-286)
  **SPONSOR:** Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of Dietary Supplements, Office of Research on Women’s Health
  **Synopsis:** The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting research projects in collaboration with NIH intramural investigators. In order to be eligible for this program, the application must include at least one intramural scientist as Program Director/Principal Investigator or collaborator, and at least some of the research must be conducted at the NIH Clinical Center. The X02 pre-application is the recommended (not required) first step in the application process for the companion FOA (PAR-15-287). Potential applicants should read both FOAs. Investigators whose X02 pre-applications are meritorious, can be accommodated by the resources of the NIH Clinical Center and the relevant intramural program, and align with the research missions of the participating NIH Institutes, will be notified of the opportunity to submit a U01 application under PAR-15-287.
  Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Opportunities for Collaborative Research at the NIH Clinical Center (U01)
  (PAR-15-287)
  **SPONSOR:** Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of Dietary Supplements, Office of Research on Women’s Health
  **Synopsis:** The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. Through this collaboration, external researchers may gain access to the NIH Clinical Center and leverage the diverse Clinical Center resources, expertise, and infrastructure available to test promising laboratory- and animal-based discoveries with potential for advancing disease diagnosis, treatment and prevention. The special environment of the Clinical Center
can support studies that may not be readily supported elsewhere. This may include collaborations that propose targeted increases in new patients enrolled in protocols at the Clinical Center. The companion FOA (PAR-15-286) encourages X02 pre-applications for Opportunities for Collaborative Research at the NIH Clinical Center. The X02 pre-application is the recommended (not required) first step in the application process for this FOA. Potential applicants should read both FOAs. Investigators whose X02 pre-applications are meritorious, can be accommodated by the resources of the NIH Clinical Center and the relevant intramural program, and align with the research missions of the participating NIH Institutes, will be notified of the opportunity to submit a U01 application to this FOA.

Application Receipt/Submission Date(s): Multiple dates see announcement.

**TITLE: PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])**

**SPONSOR:** National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Institute on Minority Health and Health Disparities, National Library of Medicine, National Center for Complementary and Integrative Health, National Center for Advancing Translational Sciences, Division of Program Coordination, Planning and Strategic Initiatives, Center For Surveillance, Epidemiology and Laboratory Services, National Center for Health Statistics, National Center for Injury Prevention and Control National Institute for Occupational Safety and Health, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Food Safety and Applied Nutrition, Center for Devices and Radiological Health Center for Veterinary Medicine, Office of Critical Path Programs, Office of Orphan Products Development Office of Planning, Research and Evaluation, Administration for Children and Families

**Synopsis:** This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics.

Application Receipt/Submission Date(s): Multiple dates see announcement.

**TITLE: Direct Phase II SBIR Grants to Support Extended Development, Hardening, and Dissemination of Technologies in Biomedical Computing, Informatics, and Big Data Science (R44)**

**SPONSOR:** National Institute of Biomedical Imaging and Bioengineering, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Human Genome Research Institute, National Institute on Aging, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

**Synopsis:** This FOA is for applications that have completed the proof of concept Phase I stage-type of research through other (non-SBIR) funding sources. The NIH is interested in promoting a broad base of research and development of a broad base of innovative technologies in biomedical computing, informatics, and Big Data Science that will support rapid progress in areas of scientific opportunity in biomedical research. It is expected that this research and development is conducted in the context of important biomedical and behavioral research problems. As such, applications are intended to develop enabling technologies that could apply to the interests of most NIH Institutes and Centers and range from basic biomedicine to research in all relevant organ systems and diseases. Major themes of research include collaborative environments; data integration; analysis and modeling methodologies; and novel computer science and statistical approaches. The proposed work should apply best practices and proven methods for software design, construction, and implementation to extend the applicability of existing technologies in biomedical computing, informatics and big data science to a broader biomedical research community.

Application Receipt/Submission Date(s): Multiple dates see announcement.

**TITLE: The Pancreatic Cancer Detection Consortium (U01)**

**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014
Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units. The Units will undertake studies on the following areas: identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; conduct biomarker validation studies; and collect longitudinal biospecimens for the establishment of a biorepository.

Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Physical activity and weight control interventions among cancer survivors: Effects on biomarkers of prognosis and survival (R01) (PAR-12-228)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications must test the effects of physical activity or weight control or both interventions on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research, which may include but are not limited to intervention-induced changes in sex hormones, insulin or insulin-like growth factors or their binding proteins, insulin resistance, glucose metabolism, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins. This research will require transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.
  Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Biomarkers for Early Detection of Hematopoietic Malignancies (R21) (PA-12-220)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages research projects for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies.
  Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Stem Cells and Alcohol-Induced Tissue Injuries (R21) (PA-12-232)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages applications to study human and non-human stem cells involved in alcohol-induced tissue injuries. Alcohol abuse is known to cause pathology in a number of organ systems. Disorders most commonly associated with chronic alcohol consumption include alcoholic liver disease (ALD), pancreatitis, cardiovascular disease, neural damage, endocrine dysfunction, osteoporosis, cancer, and immune dysfunction. The objective of this FOA is to understand the role of stem cells in alcohol-induced tissue damage and recovery, particularly how they are influenced by alcohol metabolism and their role in alcohol-related cancers.
  Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Innovative Research in Cancer Nanotechnology (IRCN) (U01) (PAR-14-285)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is an integral component of a broader program - the NCI Alliance for Nanotechnology in Cancer (The Alliance) (http://nano.cancer.gov). IRCN awards are designed to enable multi-disciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial interactions with biological systems and/or mechanisms of their in vivo delivery.
  Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44) (PAR-13-327)
SPONSOR: National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Examination of Survivorship Care Planning Efficacy and Impact [R01] (PA-12-275)

  SPONSOR: National Cancer Institute

  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to evaluate the effect of care planning on cancer survivors’ health and psychosocial outcomes; self-management of late effects and adherence to cancer screening and health behavior guidelines; utilization of follow-up care; organizational-level factors influencing the implementation of care planning; and associated costs. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors’ morbidity, self-management and adherence to care recommendations, utilization of follow-up care, and on systems outcomes, such as associated costs and impact on organizations implementing care planning; and 3) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors.

  Application Receipt/Submission Date(s): Multiple dates see announcement.

- **TITLE:** Revisions to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC) (P50) (PAR-13-298)

  SPONSOR: National Cancer Institute

  **Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications (formerly called “competing revisions”) from currently funded NIH P50 Center. These revision applications are expected to focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer. Studies proposed in the revision applications must correspond to an additional project expanding the scope of the entire parent P50 award.

  Application Receipt/Submission Date(s): Letter of Intent 30 days before the due date, Application due December 11, 2015 by 5:00pm local time of applicant organization.

- **TITLE:** Revisions to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC) (P01) (PAR-13-297)

  SPONSOR: National Cancer Institute

  **Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications (formerly called “competing revisions”) from currently funded NIH P01 program projects. These revision applications are expected to focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer. Studies proposed in the revision applications must correspond to a new research project expanding the scope of the parent Program Project grant.

  Application Receipt/Submission Date(s): Letter of Intent 30 days before the due date, Application due December 11, 2015 by 5:00pm local time of applicant organization.

- **TITLE:** Systemic Amyloidosis: Basic, Translational, and Clinical Research (R01) (PA-13-286)

  SPONSOR: National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute, National Institute on Aging

  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified basic science and clinical investigators to submit applications for research projects designed to advance the understanding of pathogenic mechanisms underlying systemic amyloidosis, to develop improved techniques (in particular those that are non-invasive) for the clinical detection and diagnosis of systemic amyloid diseases, to develop novel cellular and in vivo models with which to identify candidate therapeutic agents, and to evaluate the clinical efficacy of novel therapies designed to prevent, arrest, and (when possible) reverse the morbid and lethal progression of these diseases.
• **TITLE:** High Throughput Screening (HTS) to Discover Chemical Probes (R01)  
  (PAR-14-284)  
  **SPONSOR:** National Institute of Mental Health, **National Cancer Institute**, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, **Eunice Kennedy Shriver** National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.

• **TITLE:** Ethical, Legal, and Social Implications (ELSI) of Genomic Research Small Research Grant Program (R03)  
  (PA-14-277)  
  **SPONSOR:** National Human Genome Research Institute, **National Cancer Institute**, National Institute on Aging, National Institute of Allergy and Infectious Diseases, **Eunice Kennedy Shriver** National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, Fogarty International Center  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications should propose small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues.

• **TITLE:** Ethical, Legal, and Social Implications (ELSI) of Genomic Research Exploratory/Developmental Research Program (R21)  
  (PA-14-278)  
  **SPONSOR:** National Human Genome Research Institute, **National Cancer Institute**, National Institute on Aging, National Institute of Allergy and Infectious Diseases, **Eunice Kennedy Shriver** National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse, National Institute of Environmental Health Sciences  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Program Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications should propose exploratory or developmental studies that break new ground or extend previous discoveries in new directions. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

• **TITLE:** Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21]  
  (PA-12-284)  
  **SPONSOR:** National Institute of Biomedical Imaging and Bioengineering, **National Cancer Institute**, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, **Eunice Kennedy Shriver** National Institute of Child Health and Human Development, National Institute of Dental and Craniofacial Research, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, Office of Research on Women’s Health  
  **Synopsis:** The purpose of this FOA is to encourage Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

• **TITLE:** Discovery of in vivo Chemical Probes (R01)  
  (PAR-14-279)  
  **SPONSOR:** National Institute of Mental Health, **National Cancer Institute**, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Environmental Health Sciences, Fogarty International Center, National Institute on Deafness and Other Communication Disorders, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Drug Abuse, National Institute of Neurological Disorders and Stroke, Office of Research on Women’s Health  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.
Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse

**Synopsis:** This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.

**Application Receipt/Submission Date(s):** Multiple dates see announcement.

**OTHER FUNDING OPPORTUNITIES**
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE:** Development of Assays for High-Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01)  
  **SPONSOR:** National Institute of Mental Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institute of General Medical Sciences, National Institute on Drug Abuse, National Institute on Aging, The Eunice Kennedy Shriver National Institute of Child Health and Human Development  
  **Synopsis:** Through this FOA, NIH wishes to stimulate research in 1) developing assays for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; and 2) establishing collaboration with screening centers that have the requisite expertise and experience needed in implementation of HTS assays for the discovery and development of small molecule chemical probes. This FOA seeks to establish a stream of scientifically and technologically outstanding assays for screening by the NIH Molecular Libraries Production Centers Network (MLPCN) in the Molecular Libraries Program (MLP) and other academic centers. One important criterion for this initiative is novelty, so applicants are therefore encouraged to avoid focusing on areas and approaches that have been extensively targeted in other settings.
  **Application Receipt/Submission Date(s):** Multiple dates see announcement.

- **TITLE:** Grant and Fellowship Program - Scholar Award  
  **SPONSOR:** Leukemia & Lymphoma Society, Career Development Program  
  **Synopsis:** New for FY15, the Horizon Award supports junior level scientists to conduct impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor). The Horizon Award challenges junior scientists to develop and implement research in the cancer field. This initiative is novelty, so applicants are therefore encouraged to avoid focusing on areas and approaches that have been extensively targeted in other settings.
  **Application Receipt/Submission Date(s):** Pre-Application (Letter of Intent): August 11, 2015; Application: September 29, 2015.

- **TITLE:** Grant and Fellowship Program- Grants & Fellowships  
  **SPONSOR:** Prevent Cancer Foundation

- **TITLE:** Academic Grants: Career Development Program - Fellow Award  
  **SPONSOR:** Leukemia & Lymphoma Society

- **TITLE:** Scholar in Clinical Research Awards  
  **SPONSOR:** Leukemia & Lymphoma Society

- **TITLE:** CONquer canCER Now Award  
  **SPONSOR:** Concern Foundation

- **TITLE:** Postdoctoral Fellowship  
  **SPONSOR:** Hope Funds for Cancer Research
• TITLE: Urology Care Foundation Research Scholars Program
http://www.auanet.org/research/research-scholar-awards.cfm
SPONSOR: American Urological Association, Urology Care Foundation

• TITLE: AST Transplantation and Immunology Research Network (TIRN): Translational Science Fellowship Research Grant
http://www.tirn.org/funding
SPONSOR: American Society of Transplantation

• TITLE: Psychosocial: Family Impact Grants
http://www.alexslemonade.org/grants/program-areas/quality-life-and-care#program-141
SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer

• TITLE: Psychosocial: Launch Grants
http://www.alexslemonade.org/grants/program-areas/quality-life-and-care#program-141
SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer

• TITLE: Avon Breast Health Outreach Program
http://avonbhop.org/index.php?option=com_content&view=article&id=252&Itemid=279
SPONSOR: Avon Foundation for Women, Avon Foundation Breast Cancer Crusade

• TITLE: Young Investigator Award
http://www.conquercancerfoundation.org/cancer-professionals/funding-opportunities/young-investigator-award
SPONSOR: American Society of Clinical Oncology, Conquer Cancer Foundation

• TITLE: ASC Foundation Patient Advocacy Grant
SPONSOR: American Society of Clinical Oncology, Conquer Cancer Foundation

• TITLE: Nurse Researcher Grants: Discovery Grant: Independent Nurse Researcher
http://www.alexslemonade.org/grants/program-areas/quality-life-and-care#program-141
SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer

• TITLE: Healthy Living Grant Program
SPONSOR: American Medical Association Foundation

• TITLE: Nurse Researcher Grants: Nurse Researcher Fellowship
http://www.alexslemonade.org/grants/program-areas/quality-life-and-care#program-141
SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer

• TITLE: Independent Grants for Learning & Change (IGL&C): Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Metastatic Breast Cancer
http://www.pfizer.com/responsibility/grants_contributions/grants_process
SPONSOR: Pfizer, Inc.

• TITLE: Independent Grants for Learning & Change (IGL&C): Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Rheumatoid Arthritis and Comorbid Conditions (Management of Comorbid Conditions in Patients With RA)
http://www.pfizer.com/responsibility/grants_contributions/grants_process
SPONSOR: Pfizer, Inc.

• TITLE: Career Development Award (CDA)
http://www.conquercancerfoundation.org/cancer-professionals/funding-opportunities/career-development-award
SPONSOR: American Society of Clinical Oncology, Conquer Cancer Foundation